Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About REGN Interactive Breakdown Better Bets vs. REGN Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Regeneron Pharmaceuticals (REGN)

Market Price (10/24/2025): $576.88 | Market Cap: $60.6 Bil
Sector: Health Care | Industry: Biotechnology

Regeneron Pharmaceuticals (REGN)

Market Price (10/24/2025): $576.88
Market Cap: $60.6 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1%, FCF Yield is 5.9%		 Weak multi-year price returns
2Y Excs Rtn is -86%, 3Y Excs Rtn is -101%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 25%, CFO LTM is 4.7 Bil, FCF LTM is 3.6 Bil		  
3 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%		  
4 Low stock price volatility
Vol 12M is 40%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1%, FCF Yield is 5.9%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 25%, CFO LTM is 4.7 Bil, FCF LTM is 3.6 Bil
3 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%
4 Low stock price volatility
Vol 12M is 40%
5 Weak multi-year price returns
2Y Excs Rtn is -86%, 3Y Excs Rtn is -101%
6 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%

Market Valuation & Key Metrics

REGNS&P 500
REVENUE GROWTHPOOR
Rev LTM ($ Bil)14.2
Rev Chg Q3.6%6.2%
Rev Chg LTM5.4%5.1%
Rev Chg 3Y Avg0.3%5.4%
PROFITABILITYVERY GOOD
Op Inc LTM ($ Bil)3.8
CFO LTM ($ Bil)4.7
Net Inc LTM ($ Bil)4.5
Op Mgn LTM27.0%18.6%
CFO/Rev LTM33.4%20.4%
Net Inc Mgn31.4%12.7%
VALUATIONMODERATE
P/S4.33.2
P/CFO12.815.9
P/FCF17.021.1
P/E13.624.2
STABILITYVERY GOOD
Debt/Equity0.040.21
Cash/Assets0.200.07

REGN Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
REGN Return29%31%14%22%-19%-19%55%
Peers Return-2%2%20%-5%-12%8%8%
S&P 500 Return16%27%-19%24%23%15%106%

Monthly Win Rates [3]
REGN Win Rate50%67%50%58%50%44% 
Peers Win Rate50%47%53%42%45%49% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
REGN Max Drawdown-10%-8%-13%-6%-20%-32% 
Peers Max Drawdown-22%-13%-13%-21%-25%-14% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: AMGN, GILD, BIIB, BMRN, JAZZ. See REGN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/23/2025 (YTD)

How Low Can It Go

Unique KeyEventREGNS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-25.8%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven34.7%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven112 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-27.3%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven37.6%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven233 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-48.1%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven92.5%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven202 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-57.9%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven137.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven329 days1480 days

Compare to AMGN, GILD, BIIB, BMRN, JAZZ


In The Past

Regeneron Pharmaceuticals's stock fell -25.8% during the 2022 Inflation Shock from a high on 4/8/2022. A -25.8% loss requires a 34.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Regeneron Pharmaceuticals (REGN)

Better Bets than Regeneron Pharmaceuticals (REGN)

 REGNBetter Performance than REGN
MetricValueIndustry (Biotechnology)
Rev Chg LTM5.4%ABBV (6.1%), AMGN (12.9%), VRTX (10.5%), ALNY (17.2%), INSM (21.2%)
Rev Chg 3Y Avg0.3%ABBV (0.6%), AMGN (10.0%), GILD (1.6%), VRTX (11.0%), ALNY (40.8%)
Op Mgn LTM27.0%GILD (37.4%), UTHR (50.1%), RPRX (79.8%), EXEL (33.7%), HALO (57.9%)
CFO/Rev LTM33.4%AMGN (34.4%), GILD (34.2%), VRTX (33.7%), UTHR (44.6%), RPRX (104.4%)
FCF/Rev LTM25.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), UTHR (34.8%)
Total Yield7.7%RPRX (9.0%), PTCT (12.1%), CPRX (8.2%), AGIO (26.7%), HRMY (10.6%)
 REGNBetter Performance than REGN
MetricValueAll Other Sectors
Rev Chg LTM5.4%NVDA (71.6%), AAPL (6.0%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.3%NVDA (92.0%), AAPL (1.8%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM27.0%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM33.4%NVDA (46.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%), AVGO (42.4%)
FCF/Rev LTM25.0%NVDA (43.6%), MSFT (25.4%), META (30.7%), AVGO (41.6%), V (56.8%)
Total Yield7.7%XOM (9.6%), BABA (36.7%), WFC (9.5%), CVX (9.5%), TM (2049.8%)
 Best Bets In Health Care Sector
 REGNRPRX HALO CPRX LNTH PBH EW HCA UHS CI ELV
What You Pay           
P/E13.615.314.612.114.314.510.817.610.616.414.0
P/EBIT12.38.111.410.49.89.326.89.67.39.99.1
What You Get           
Rev Chg Q3.6%7.7%40.8%19.4%-4.1%-6.6%11.9%6.4%9.6%18.2%12.3%
Rev Chg LTM5.4%3.0%35.0%28.5%5.7%0.6%9.1%6.4%9.6%24.6%12.0%
Rev Chg 3Y Avg0.3%0.8%35.5%49.9%34.3%0.8%3.0%6.6%8.1%13.2%8.4%
FCF/Rev 3Y Avg24.1%113.4%43.4%38.9%26.1%21.6%11.9%8.4%4.9%4.3%2.4%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Regeneron Pharmaceuticals Earnings Notes  
2Is Wall Street Undervaluing Regeneron Pharmaceuticals Stock?Actionable 
3How Low Can Regeneron Pharmaceuticals Stock Really Go?Return 
4Big Move for REGN, but Do UTHR's Margins and Growth Give It the Edge?Counter-Intuitive Comparisons 
5How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers?Peer Comparison 
6Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, SO   
7Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, UTHR   
8Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UTHR, EXEL   
9Day 5 of Gains Streak for Regeneron Pharmaceuticals Stock with 6% Return (vs. -20% YTD) [7/14/2025]  
10REGN Dip Buy Analysis  
11ARTICLES  
12What If You Were Missing The Value In Regeneron Pharmaceuticals Stock? October 10th, 2025
13REGN Jumps 6.7% in a Day, But Does UTHR Offer Better Fundamentals? October 2nd, 2025
14REGN Stock Up 6% after 5-Day Win Streak July 15th, 2025
15Is It Time To Buy Regeneron Pharmaceuticals Stock? June 2nd, 2025
16Is Regeneron Stock Fully Valued At $820? September 8th, 2023
Title
0DASHBOARDS
1What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?
2REGN Jumps 6.7% in a Day, But Does UTHR Offer Better Fundamentals?
3REGN Stock Up 6% after 5-Day Win Streak
4Is It Time To Buy Regeneron Pharmaceuticals Stock?
5Is Regeneron Stock Fully Valued At $820?
6ARTICLES
7Regeneron Pharmaceuticals Earnings Notes
8Is Wall Street Undervaluing Regeneron Pharmaceuticals Stock?
9How Low Can Regeneron Pharmaceuticals Stock Really Go?
10Big Move for REGN, but Do UTHR's Margins and Growth Give It the Edge?
11How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers?
12Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, SO 
13Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, UTHR 
14Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UTHR, EXEL 
15Day 5 of Gains Streak for Regeneron Pharmaceuticals Stock with 6% Return (vs. -20% YTD) [7/14/2025]
16REGN Dip Buy Analysis

Trade Ideas

Select past ideas related to REGN. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.4%3.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.0%4.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.6%6.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.9%15.9%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		12.9%12.9%-8.0%
REGN_3312025_Dip_Buyer_FCFYield03312025REGNRegeneron PharmaceuticalsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		-11.3%-7.5%-23.7%
REGN_5312019_Dip_Buyer_FCFYield05312019REGNRegeneron PharmaceuticalsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		22.3%103.1%-9.4%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.4%3.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		4.0%4.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.6%6.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.9%15.9%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		12.9%12.9%-8.0%
REGN_3312025_Dip_Buyer_FCFYield03312025REGNRegeneron PharmaceuticalsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		-11.3%-7.5%-23.7%
REGN_5312019_Dip_Buyer_FCFYield05312019REGNRegeneron PharmaceuticalsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		22.3%103.1%-9.4%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor53.8%92.4%
2BETRBetter Home & Finance49.4%864.9%
3BALYBallys46.7%4.6%
4CLBCore Laboratories44.2%-4.7%
5LBRTLiberty Energy35.8%-16.8%
6CELCCelcuity34.3%439.1%
7WGOWinnebago Industries31.4%-14.3%
8CCOClear Channel Outdoor31.0%35.8%
9PMIPicard Medical28.2%20852.4%
10ISRGIntuitive Surgical26.8%5.6%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1ITGRInteger-28.3%-44.2%
2METCRamaco Resources-27.2%256.2%
3SESSES AI-24.5%8.2%
4SLIStandard Lithium-23.7%181.5%
5QBTSD-Wave Quantum-23.2%269.8%
6OKLOOklo-23.1%487.4%
7INBXInhibrx Biosciences-22.5%84.2%
8LENZLENZ Therapeutics-22.4%8.7%
9ASMAvino Silver & Gold Mines-21.6%476.6%
10SMRNuScale Power-21.2%109.5%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1232.9%344.3%
2PRAXPraxis Precision Medicines263.5%131.3%
3NVTSNavitas Semiconductor98.4%281.2%
4ORKAOruka Therapeutics77.7%39.9%
5GRALGRAIL77.4%363.0%
6VICRVicor76.1%92.4%
7UAMYUnited States Antimony75.9%562.7%
8PMIPicard Medical69.9%20852.4%
9BALYBallys68.8%4.6%
10SNDKSanDisk67.3% 

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1FLYFirefly Aerospace-36.0% 
2SOCSable Offshore-35.6%-38.8%
3VGVenture Global-33.7% 
4FWRDForward Air-31.6%-41.2%
5NFENew Fortress Energy-31.1%-88.3%
6GOSSGossamer Bio-30.1%131.0%
7USNAUsana Health Sciences-28.6%-42.5%
8ITGRInteger-28.2%-44.2%
9RCReady Capital-27.5%-50.8%
10PSIXPower Solutions International-27.4%170.7%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor53.8%92.4%
2BETRBetter Home & Finance49.4%864.9%
3BALYBallys46.7%4.6%
4CLBCore Laboratories44.2%-4.7%
5LBRTLiberty Energy35.8%-16.8%
6CELCCelcuity34.3%439.1%
7WGOWinnebago Industries31.4%-14.3%
8CCOClear Channel Outdoor31.0%35.8%
9PMIPicard Medical28.2%20852.4%
10ISRGIntuitive Surgical26.8%5.6%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1ITGRInteger-28.3%-44.2%
2METCRamaco Resources-27.2%256.2%
3SESSES AI-24.5%8.2%
4SLIStandard Lithium-23.7%181.5%
5QBTSD-Wave Quantum-23.2%269.8%
6OKLOOklo-23.1%487.4%
7INBXInhibrx Biosciences-22.5%84.2%
8LENZLENZ Therapeutics-22.4%8.7%
9ASMAvino Silver & Gold Mines-21.6%476.6%
10SMRNuScale Power-21.2%109.5%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Regeneron Pharmaceuticals

Financials

REGNAMGNGILDBIIBBMRNJAZZMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.Jazz Pha. 
Mkt Price575.69292.89120.74150.0854.55138.18144.13
Mkt Cap60.5157.6150.321.910.58.541.2
Rev LTM14,21434,91728,8629,8163,0644,08712,015
Op Inc LTM3,8418,19210,7972,2747766143,058
FCF LTM3,55610,6059,3692,2966911,2402,926
FCF 3Y Avg3,2488,5908,3971,6673151,0802,458
CFO LTM4,74412,0139,8682,5827671,3163,663
CFO 3Y Avg4,5189,7538,9491,9684191,2563,243

Growth & Margins

REGNAMGNGILDBIIBBMRNJAZZMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.Jazz Pha. 
Rev Chg LTM5.4%12.9%3.8%1.6%18.4%4.5%4.9%
Rev Chg 3Y Avg0.3%10.0%1.6%-3.1%17.0%5.5%3.6%
Rev Chg Q3.6%9.4%1.8%6.1%15.9%2.1%4.9%
QoQ Delta Rev Chg LTM0.9%2.3%0.4%1.5%3.8%0.5%1.2%
Op Mgn LTM27.0%23.5%37.4%23.2%25.3%15.0%24.4%
Op Mgn 3Y Avg30.1%26.4%39.2%23.4%14.0%14.9%24.9%
QoQ Delta Op Mgn LTM-0.2%1.6%-0.0%0.2%4.3%0.4%0.3%
CFO/Rev LTM33.4%34.4%34.2%26.3%25.0%32.2%32.8%
CFO/Rev 3Y Avg33.6%32.0%31.9%20.0%15.0%32.1%31.9%
FCF/Rev LTM25.0%30.4%32.5%23.4%22.6%30.3%27.7%
FCF/Rev 3Y Avg24.1%28.2%30.0%16.9%10.9%27.5%25.8%

Valuation

REGNAMGNGILDBIIBBMRNJAZZMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.Jazz Pha. 
Mkt Cap60.5157.6150.321.910.58.541.2
P/S4.34.55.22.23.42.13.8
P/EBIT12.315.218.311.012.3-28.212.3
P/E13.623.823.814.815.9-20.915.4
P/CFO12.813.115.28.513.76.412.9
Total Yield7.7%7.4%6.8%6.7%6.3%-4.8%6.8%
Dividend Yield0.3%3.2%2.6%0.0%0.0%0.0%0.2%
FCF Yield 3Y Avg4.4%6.2%8.0%6.6%2.7%15.5%6.4%
D/E0.00.40.20.30.10.60.2
Net D/E-0.10.30.10.2-0.10.40.2

Returns

REGNAMGNGILDBIIBBMRNJAZZMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.Jazz Pha. 
1M Rtn1.4%2.1%5.5%7.7%2.1%6.8%3.8%
3M Rtn2.1%-4.3%7.4%13.2%-8.7%17.1%4.8%
6M Rtn-3.7%6.4%15.3%25.6%-13.1%26.8%10.9%
12M Rtn-38.6%-3.9%42.5%-18.0%-22.0%24.3%-10.9%
3Y Rtn-21.6%23.3%94.8%-45.3%-39.3%2.5%-9.5%
1M Excs Rtn-1.7%3.4%4.7%7.5%-0.1%5.1%4.0%
3M Excs Rtn-3.1%-9.2%-0.8%8.6%-13.0%11.4%-2.0%
6M Excs Rtn-26.6%-16.4%-7.5%2.7%-35.9%3.9%-12.0%
12M Excs Rtn-55.4%-19.5%29.0%-33.8%-37.5%7.0%-26.7%
3Y Excs Rtn-101.1%-53.3%19.8%-125.6%-120.2%-78.8%-90.0%

Comparison Analyses

Title
0How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers?
1Regeneron Pharmaceuticals vs. Jazz Pharmaceuticals: With Return Forecast Of 133%, Jazz Pharmaceuticals Is A Better Bet
2BMRN Looks Stronger Than REGN With 46% Return Potential
3Regeneron Pharmaceuticals vs. Zoetis: With Return Forecast Of 59%, Regeneron Pharmaceuticals Is A Better Bet
4Regeneron Pharmaceuticals vs. Mondelez: With Return Forecast Of 59%, Regeneron Pharmaceuticals Is A Better Bet
5Regeneron Pharmaceuticals vs. 3M Company: With Return Forecast Of 59%, Regeneron Pharmaceuticals Is A Better Bet
6Regeneron Pharmaceuticals vs. Abbott Laboratories: With Return Forecast Of 35%, Regeneron Pharmaceuticals Is A Better Bet
7Regeneron Pharmaceuticals vs. Thermo Fisher Scientific: With Return Forecast Of 35%, Regeneron Pharmaceuticals Is A Better Bet
8Regeneron Pharmaceuticals vs. Home Depot: With Return Forecast Of 35%, Regeneron Pharmaceuticals Is A Better Bet
9Regeneron Pharmaceuticals vs. Automatic Data Processing: Similar Revenue, But Regeneron Pharmaceuticals Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/1/20254/29/20252/5/202510/31/20248/1/20245/2/20242/5/202411/2/20238/3/20235/4/20232/6/202311/3/2022
Key Financials Quarterly            
Total Revenue3,6763,0293,7893,7213,5473,1453,4343,3633,1583,1623,4142,936
Ebitda1,6571,0411,0951,6281,7648311,2791,2341,2059761,4421,618
Operating Income1,0805929901,1801,0707519731,1111,0169471,1471,224
Net Income1,3928099181,3411,4327221,1601,0089688181,1971,316
EPS13.247.588.5312.4013.256.7010.889.489.057.6411.1912.31
Key Financials TTM            
Total Revenue TTM14,21414,08614,20213,84713,48913,10013,11713,09712,67112,37012,17313,710
Ebitda TTM5,4225,5285,3185,5025,1074,5494,6934,8575,2405,0865,2606,409
Operating Income TTM3,8413,8313,9913,9733,9053,8524,0474,2214,3344,4274,7396,232
Net Income TTM4,4594,4994,4134,6544,3223,8583,9543,9914,2994,1834,3385,370
Growth Rates Quarterly            
Total Revenue Growth3.6%-3.7%10.3%10.6%12.3%-0.5%0.6%14.5%10.5%6.6%-31.0%-15.0%
EBITDA Growth-6.0%25.2%-14.4%32.0%46.4%-14.8%-11.3%-23.7%14.7%-15.1%-44.4%-15.0%
Operating Income Growth0.9%-21.3%1.8%6.2%5.2%-20.6%-15.2%-9.2%-8.4%-24.8%-56.6%-33.8%
Net Income Growth-2.8%12.0%-20.9%33.0%47.9%-11.7%-3.1%-23.4%13.6%-16.0%-46.3%-19.4%
Margins Quarterly            
EBITDA Margin45.1%34.4%28.9%43.8%49.7%26.4%37.2%36.7%38.2%30.8%42.2%55.1%
Operating Income Margin29.4%19.5%26.1%31.7%30.2%23.9%28.3%33.0%32.2%29.9%33.6%41.7%
Net Income Margin37.9%26.7%24.2%36.0%40.4%23.0%33.8%30.0%30.7%25.9%35.1%44.8%
Cash & Debt            
Total Cash7,4708,3499,0129,7969,80910,52010,8459,9148,9288,9607,7427,022
Total Debt2,7052,7052,7042,7042,7042,7032,7032,7032,7022,7022,7012,701
Net Debt / (Cash)-4,764-5,645-6,308-7,092-7,105-7,816-8,142-7,211-6,226-6,258-5,041-4,321
Cash Flows Quarterly            
FCF from Operations1,1441,0451,2631,2913541,5121,0901,1141,0221,3681,720629
Cash Flows TTM            
FCF from Operations TTM4,7443,9534,4204,2474,0704,7394,5945,2244,7394,2815,0155,668
Returns to Shareholders Quarterly            
Dividends93940000000000
Share Repurchases1,0671,0461,2268559166357476767058086201,044
Return on Invested Capital (ROIC) Quarterly            
ROIC------------
Return on Invested Capital (ROIC) TTM            
ROIC TTM------------

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
EYLEA ®5,7206,2655,7924,9474,644
Collaboration revenue5,5034,9143,673  
Libtayo ®539374306271176
Other revenue536365281557174
Libtayo324730  
Praluent ®182130170151 
EYLEA HD ®16600  
Evkeeza ®774918  
Inmazeb ®7030  
ARCALYST ®  21314
REGEN-COV ®  5,828186 
Bayer   1,1861,146
Sanofi   1,186404
Total13,11712,17316,0728,4976,558


Price Behavior

REGN Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta1.850.340.620.770.680.60
Up Beta4.230.750.510.530.540.53
Down Beta4.42-0.560.060.650.550.57
Up Capture40%45%84%94%38%22%
Bmk +ve Days13233574144420
Stock +ve Days11233465119388
Down Capture208%37%80%147%118%94%
Bmk -ve Days8192952107330
Stock -ve Days10193060131362

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity2,760,203
Short Interest: % Change Since 9152025-7.5%
Average Daily Volume1,168,677
Days-to-Cover Short Interest2.36
Basic Shares Quantity105,100,000
Short % of Basic Shares2.6%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/1/20252.5%2.6%6.6%
4/29/2025-6.9%-1.2%-3.0%
1/13/20252.9%-2.2%-4.5%
10/31/2024-9.2%-11.5%-18.7%
8/1/20241.3%-1.1%9.2%
5/2/20243.8%5.8%8.5%
2/2/2024-1.3%-1.2%1.4%
11/2/20233.5%4.0%3.0%
...
SUMMARY STATS   
# Positive181114
# Negative71411
Median Positive3.4%5.8%7.6%
Median Negative-3.7%-1.9%-4.5%
Max Positive6.9%10.7%32.9%
Max Negative-9.2%-11.5%-18.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025801202510-Q 6/30/2025
3312025429202510-Q 3/31/2025
12312024205202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024502202410-Q 3/31/2024
12312023205202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022206202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022803202210-Q 6/30/2022
3312022504202210-Q 3/31/2022
12312021207202210-K 12/31/2021
93020211104202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0RYAN ARTHUR F 10032024Sell1041.3533,12418,410,027Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.